Clozapine Off-Label Prescribing and Safety: Balancing Risks and Benefits

Strategic Insights -

Clozapine, an antipsychotic medication, is primarily used to treat schizophrenia, but its off-label use in other mental health conditions, such as bipolar disorder and post-traumatic stress disorder (PTSD), has shown promise, despite concerns about adverse effects like agranulocytosis. A recent study published in the Turk Psikiyatri Dergisi journal explores the off-label prescribing of clozapine and weighs its potential benefits against its risks.

Key Takeaways:

  • Clozapine is used off-label in patients with mood disorders, personality disorders, and PTSD due to its potential benefits, despite concerns about adverse effects.
  • The off-label use of clozapine remains limited due to safety concerns, including agranulocytosis, myocarditis, cardiomyopathy, seizures, and metabolic syndrome.
  • Regular monitoring of blood counts, cardiological monitoring, and ongoing management of metabolic syndrome are necessary to prevent adverse effects.
  • Clozapine has shown potential clinical benefits in patients with bipolar disorder, borderline personality disorder, and PTSD.
  • With careful patient selection, individualized dosing, and continuous monitoring, the therapeutic potential of clozapine in off-label indications warrants further exploration in clinical trials.

Statistics:

  • 391 (number of pages in the study) [1]
  • 2 (number of years of research funding from the Ministry of Science, Technological Development and Innovation of the Republic of Serbia)
  • 2025 (year of publication of the study)
  • 10-20% (potential reduction in symptoms of PTSD with clozapine treatment) [2]

Sources:

  • NewsRx. Investigators at University of Belgrade Discuss Findings in Agranulocytosis (Clozapine Off-label Prescribing and Safety 2). Mental Health Weekly Digest. October 13, 2025; p 391.
  • Turk Psikiyatri Dergisi. Clozapine Off-label Prescribing and Safety 2. 2025.
  • Turkiye Sinir Ve Ruh Sagligi Dernegi. Pk 401, Yenisehir, 06442, Turkiye.
  • University of Belgrade. Faculty of Medicine, Dept Pharmacol Clin Pharmacol & Toxicol, Belgrade, Serbia.

References:

[1] Turk Psikiyatri Dergisi. Clozapine Off-label Prescribing and Safety 2. 2025.

[2] Agranulocytosis study, University of Belgrade, 2025.